Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | MAPT | P10636 | 6/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.85 |
| ▸ | USP2 | O75604 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | DRD1 | P21728 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL565708 | 1.00 | LMNA (0.85) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL7623667 | 0.93 | LMNA (0.74) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Trifluoperazine SCHEMBL1590789 | 0.93 | RAD52 (0.84) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Trifluoperazine SCHEMBL1590788 | 0.93 | RAD52 (0.84) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL27704688 | 0.92 | LMNA (0.88) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL29354183 | 0.92 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL29388890 | 0.92 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL5072860 | 0.92 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL19221 | 0.92 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL7194252 | 0.91 | LMNA (0.98) | LMNAMAPTCYP3A4MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113855751-A | A Chinese and western medicinal preparation for rapidly treating dermatoses, and its preparation method | 刘华 | 2021-12-31 | — | — | CN | claimed |
| EP-3178471-B1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | BCWORLD PHARM CO LTD (KR) | 2019-06-19 | — | — | EP | claimed |
| US-20170216210-A1 | Preparation Method of Drug-Containing Sustained Release Microparticles | BC World Pharm Co.,Ltd. (KR) | 2017-08-03 | — | — | US | claimed |
| EP-3178471-A1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | Bcworld Pharm. Co., Ltd. (KR) | 2017-06-14 | — | — | EP | claimed |
| US-8399007-B2 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2013-03-19 | — | — | US | claimed |
| US-20090252777-A1 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2009-10-08 | — | — | US | claimed |
| EP-0669128-B1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL (JP) | 2000-01-05 | — | — | EP | claimed |
| US-5871778-A | Sustained release microsphere preparation containing antipsychotic drug | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0669128-A1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-08-30 | — | — | EP | claimed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| CN-116942592-A | Water-soluble biomolecular glass microneedle and preparation method thereof | 中国科学院过程工程研究所 | 2023-10-27 | — | — | CN | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-113855751-A | A Chinese and western medicinal preparation for rapidly treating dermatoses, and its preparation method | 刘华 | 2021-12-31 | — | — | CN | disclosed |
| EP-3178471-B1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | BCWORLD PHARM CO LTD (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-5871778-A | Sustained release microsphere preparation containing antipsychotic drug | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5656299-A | Sustained release microsphere preparation containing antipsychotic drug and production process thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0669128-A1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-08-30 | — | — | EP | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252777-A1 | Method for formulating a controlled-release pharmaceutical formulation | LPXN, CYP3A7, LIPA | DRD2 2601/4885LMNA 2087/4885MAPT 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.